Intermittent fasting suppressed splenic CD205+ G‐MDSC accumulation in a murine breast cancer model by attenuating cell trafficking and inducing apoptosis

Abstract

Immune‐based interventions are the most promising approach for new cancer treatments to achieve long‐term cancer‐free survival. However, the expansion of myeloid‐derived suppression cells (MDSCs) attenuates the therapeutic potential of immunotherapy. We recently showed that CD205+ granulocytic MDSCs (G‐MDSCs), but not T cells, are sensitive to glucose deficiency. Intermittent fasting (IF) may inhibit the growth of malignant cells by reducing serum glucose levels, but little is known regarding the influence of IF on MDSC expansion. Herein, we observed that IF selectively inhibited splenic accumulation of CD205+ G‐MDSCs in a 4T1 and 4T07 transplant murine breast cancer model. The efficiency of IF in suppressing tumor growth was comparable to that of docetaxel. Further examination revealed that CXCR4 expression was concentrated in CD205+ subsets of tumor‐induced G‐MDSCs. Downregulation of CXCR4 correlated with a reduction in CD205+ G‐MDSC trafficking from bone marrow to the spleen under IF treatment. In addition, ex vivo culture assays showed that glucose deficiency and 2‐deoxy‐D‐glucose (2DG) treatment selectively induced massive death of splenic CD205+ G‐MDSCs. Interestingly, 2DG emulated the phenomena of IF selectively suppressing the accumulation of CD205+ G‐MDSCs in the spleen, upregulating cleaved caspase 3 in the tumor, downregulating Ki67 in the lung, and retarding the growth of transplanted 4T1 and 4T07 murine breast tumors. These findings suggest that IF inhibited cell trafficking through the downregulation of CXCR4 and induced apoptosis by altering glucose metabolism; this, suppressed the accumulation of tumor‐induced splenic CD205+ G‐MDSCs and in turn enhanced antitumor immunity.

Abstract

We observed that intermittent fasting not only limits the growth of breast tumors but also inhibits the accumulation of immunosuppressive cells, suggesting that intermittent fasting has the potential to enhance the immune system of cancer hosts and is an adjuvant treatment option to improve the effectiveness of cancer immunotherapy.